A Russian company with technology for analysing the human genome seeks partners to conclude research cooperation agreement

The Russian company from Moscow region was founded in 2014. The company possesses technology for analysis of the human genome using high-throughput sequencing methods of 2 and 3 generations: NGS (Next generation sequencing) и TGS (Third generation sequencing. Research centres and biobanks work with the laboratory as a reference laboratory since it guarantees the timing and quality of data processing. All research results are stored on a secure server, and the company ensures their confidentiality. The company provides services such as: - panel sequencing (Highly efficient sequencing of gene panels to identify mutations that lead to the manifestation of specific hereditary diseases). - full-exome sequencing (Highly efficient sequencing of clinically significant regions of the human genome (clinical exome) to identify mutations that lead to the manifestation of hereditary diseases). - NGS and TGS sequencing (Conducting work for scientific projects using Illumina high-performance NGS platforms and third-generation sequencing on the Oxford Nanopore platform. A full range of services for the preparation and analysis of all types of DNA and RNA libraries. Analysis of RNA and DNA of viruses). - genotyping (Investigation of point mutations in genes by real-time PCR. A simple and effective method for analysing a small number of the most important genes). - Functional gene sequencing (16S 18S). - PCR tests for COVID-19. There is no experience in implementing international projects, but the company is interested in participating. There is no certification, but the company is interested in obtaining it. The company is looking for international partners such as companies, active in the pharmaceutical field, universities, and research centres. The types of partnership considered are research agreement, to explore the innovative application and research and development solution on genetic research.